copd - Search News

News

COPD, Merck and Verona

Merck spends $10 billion for Verona, gaining access to its COPD medication

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. With the acquisition, Merck gets access to Verona Pharma's chronic obstructive pulmonary disease medication Ohtuvayre.

· 4d · on MSN

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

· 3d · on MSN

Merck buys Raleigh drugmaker for $10 billion, drawn by new COPD treatment

WBAL-TV21h

COPD in Women: How the condition presents differently in female patients

Dr. Albert J. Polito from Mercy Medical Center joins Jenyne for a conversation about lung conditions such as COPD and asthma and how they present in female patients.

Fierce Pharma4d

Respiratory pharma royalty rally around rural COPD education and support drive

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

The Lancet3d

Transforming COPD management: the role of dupilumab

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

MedPage Today on MSN4d

Switch to Dry-Powder Inhaler Worsened COPD, Asthma Patient Outcomes

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

The American Journal of Managed Care3d

Itepekimab Shows Mixed Results in Phase 3 COPD Trials

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Healio12d

Q&A: Mepolizumab marks second biologic approved for COPD with eosinophilic phenotype

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Zacks.com on MSN2d

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Fierce Pharma4d

Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Physician's Weekly10d

Q&A: Can Digital Inhalers Predict Exacerbations of COPD?

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

News Medical on MSN4d

Vaping linked to higher COPD risk, meta-analysis finds

A comprehensive meta-analysis of over 4.3 million adults shows e-cigarette use is associated with significantly higher odds ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results